Solomon Moshkevich Sells 549 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 549 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total value of $57,732.84. Following the sale, the insider now directly owns 113,637 shares in the company, valued at $11,950,066.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, May 28th, Solomon Moshkevich sold 1,647 shares of Natera stock. The stock was sold at an average price of $109.96, for a total transaction of $181,104.12.

Natera Stock Up 1.0 %

Natera stock traded up $1.01 during mid-day trading on Tuesday, hitting $106.52. 895,366 shares of the company’s stock were exchanged, compared to its average volume of 1,329,804. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $117.23. The stock has a 50 day moving average of $109.29 and a two-hundred day moving average of $91.89. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The stock has a market cap of $13.08 billion, a P/E ratio of -34.14 and a beta of 1.48.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. During the same quarter in the prior year, the firm posted ($1.23) EPS. The firm’s revenue for the quarter was up 52.1% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -2.43 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent analyst reports. The Goldman Sachs Group raised their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Piper Sandler raised their target price on Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 14th. BTIG Research upped their price target on Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Craig Hallum initiated coverage on Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective for the company. Finally, StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $101.19.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the company. Principal Securities Inc. acquired a new position in Natera in the 4th quarter valued at $32,000. GAMMA Investing LLC grew its position in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the last quarter. YHB Investment Advisors Inc. bought a new position in Natera in the 1st quarter worth approximately $36,000. Oliver Lagore Vanvalin Investment Group grew its stake in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares during the last quarter. Finally, Arcadia Investment Management Corp MI increased its position in Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after acquiring an additional 174 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.